Istiratumab

Drug Profile

Istiratumab

Alternative Names: MM-141

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Adimab
  • Developer Adimab; Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Ovarian cancer

Most Recent Events

  • 15 Nov 2016 Phase-I trials in Solid-tumours (Late-stage disease) in France and USA (Parenteral)
  • 15 Nov 2016 Adverse events, pharmacokinetic and pharmacodynamic data from a phase I trial in solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top